Skip to main content

Advertisement

SpringerLink
Log in

Management of Peripheral T-cell Lymphomas and the Role of Transplant

  • Lymphomas (T Hilal, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Here, we review the management of peripheral T-cell lymphoma, particularly focusing on the role of autologous and allogeneic stem cell transplant.

Recent Findings

Peripheral T-cell lymphomas are a rare subset of non-Hodgkin’s lymphomas that are treated with curative intent. While therapy has been based on other aggressive lymphoid malignancies, outcomes are generally poorer than B-cell lymphomas with 5-year overall and progression-free survival of 30–40% and 20–30%, respectively. In effort to improve outcomes, transplant has been used in both the frontline and salvage settings. Although not studied in randomized studies, consolidation with autologous stem cell transplant in first remission has been associated with an approximate 5-year overall survival of 50–60% and 5-year progression-free survival of 40–45%. Unfortunately, most patients relapse, and, in this setting, allogeneic transplant remains the only curative option for those who are transplant-eligible. Multiple series have now shown that 3-year overall survival with allogeneic transplant is approximately 60%. However, outcomes with transplant are associated with disease control at the time of transplant.

Summary

In contrast to B-cell malignancies, treatment decisions for peripheral T-cell lymphomas are supported mostly by phase II studies, retrospective series, and expert opinion. For patients with peripheral T-cell lymphoma able to achieve sufficient disease control, autologous stem cell transplantation in first remission and allogeneic stem cell transplantation in relapsed disease offer modest benefit over chemotherapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood [Internet]. 2016 [cited 2021 Dec 12];127:2375–90. Available from: https://doi.org/10.1182/blood-2016-01-643569

  2. Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, et al. Analysis of peripheral T-cell lymphoma diagnostic workup in the United States. Clin Lymphoma Myeloma Leuk. 2017;17:193–200.

    Article  PubMed  Google Scholar 

  3. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Annals of Oncology [Internet]. Elsevier; 1998 [cited 2022 Mar 16];9:717–20. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)55920-8/fulltext

  4. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

  5. Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol. 2014;99:227–39.

    Article  CAS  PubMed  Google Scholar 

  6. de Leval L, Parrens M, Le Bras F, Jais J-P, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica [Internet]. 2015 [cited 2022 Mar 19];100:e361–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800690/

  7. Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer [Internet]. 2017 [cited 2022 Mar 15];123:1174–83. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650190/

  8. M.A. Shipp. A predictive model for aggressive non-Hodgkin’s lymphoma. NEJM [Internet]. Massachusetts Medical Society; 1993;329:987–94. Available from: https://doi.org/10.1056/NEJM199309303291402

  9. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.

    Article  CAS  PubMed  Google Scholar 

  10. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.

    Article  CAS  PubMed  Google Scholar 

  11. Vose JM, The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood [Internet]. [cited 2022 Mar 26];106:811. Available from. 2005. https://doi.org/10.1182/blood.V106.11.811.811.

    Article  Google Scholar 

  12. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology [Internet]. 2018 [cited 2022 Mar 22];181:760–9. Available from: https://doi.org/10.1111/bjh.15258

  13. Gutiérrez-García G, García-Herrera A, Cardesa T, Martínez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Annals of Oncology [Internet]. Elsevier; 2011 [cited 2022 Mar 26];22:397–404. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)38661-2/fulltext

  14. Malecek M-K, Mehta-Shah N. Prognosis and risk stratification of peripheral T-cell lymphomas. Semin Hematol. 2021;58:70–7.

    Article  PubMed  Google Scholar 

  15. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Annals of Oncology [Internet]. Elsevier; 2004 [cited 2022 Mar 15];15:1467–75. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)51047-X/fulltext

  16. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood [Internet]. 2014 [cited 2022 Mar 15];124:1570–7. Available from:https://doi.org/10.1182/blood-2014-04-573089

  17. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.

    Article  CAS  PubMed  Google Scholar 

  18. d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  PubMed  Google Scholar 

  19. Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40.

    Article  CAS  PubMed  Google Scholar 

  20. Horwitz S, O’Connor OA, Pro B, Trümper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288–98.

    Article  CAS  PubMed  Google Scholar 

  21. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood [Internet]. 2010 [cited 2022 Mar 15];116:3418–25. Available from: https://doi.org/10.1182/blood-2010-02-270785

  22. Altmann B, Wulf G, Truemper L, d’Amore F, Relander T, Toldbod H, et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1/2 phase III trials. Blood [Internet]. 2018 [cited 2022 Mar 27];132:1622. Available from: https://doi.org/10.1182/blood-2018-99-112076

  23. Bachy E, Camus V, Thieblemont C, Casasnovas R-O, Ysebaert L, Damaj GL, et al. Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood [Internet]. American Society of Hematology; 2020 [cited 2022 Apr 5];136:32–3. Available from: http://ashpublications.org/blood/article/136/Supplement 1/32/469958/Final-Analysis-of-the-Ro-CHOP-Phase-III-Study

  24. Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535–44.

    Article  CAS  PubMed  Google Scholar 

  25. Lunning MA, Horwitz SM, Advani R, Vose JM, Lee HJ, Mehta-Shah N, et al. Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-Cell lymphoma: phase II results. Blood [Internet]. 2018 [cited 2022 Mar 27];132:2899. Available from:https://doi.org/10.1182/blood-2018-99-114110

  26. d’Amore F, Gaulard P, Trümper L, Corradini P, Kim W-S, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108-115.

    Article  PubMed  Google Scholar 

  27. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826–38.

    Article  PubMed  Google Scholar 

  28. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.

    Article  CAS  PubMed  Google Scholar 

  29. Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer Journal [Internet]. Nature Publishing Group; 2016 [cited 2022 Mar 14];6:e452–e452. Available from: https://www.nature.com/articles/bcj201663

  30. García-Sancho AM, Bellei M, López-Parra M, Gritti G, Cortés M, Novelli S, et al. Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. Haematologica. 2022;

  31. Savage KJ, Horwitz SM, Advani RH, Christensen JH, Domingo-Domenech E, Rossi G, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. Blood [Internet]. American Society of Hematology; 2019 [cited 2022 Apr 5];134:464–464. Available from: http://ashpublications.org/blood/article/134/Supplement_1/464/426343/An-Exploratory-Analysis-of-Brentuximab-Vedotin

  32. Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507–17.

    Article  CAS  PubMed  Google Scholar 

  33. Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.

    Article  CAS  PubMed  Google Scholar 

  34. Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood [Internet]. 2021 [cited 2022 Feb 25];137:2646–56. Available from:https://doi.org/10.1182/blood.2020008825

  35. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood [Internet]. 2014 [cited 2022 Mar 22];123:2915–23. Available from: https://www.sciencedirect.com/science/article/pii/S0006497120356500

  36. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186:e28-31.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Advances [Internet]. 2019 [cited 2022 Apr 10];3:187–97. Available from:https://doi.org/10.1182/bloodadvances.2018024075

  39. Shustov AR, Wilson WH, Beaven AW, Savage KJ, Carson KR, Hernandez-Ilizaliturri FJ, et al. Hepatosplenic T-cell lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium. Blood [Internet]. 2013 [cited 2022 May 3];122:3032. Available from: https://doi.org/10.1182/blood.V122.21.3032.3032

  40. David KA, Pulitzer M, Guitart J, Martinez-Escala ME, Geller S, Wang Y, et al. Characteristics, treatment patterns, and outcomes in primary cutaneous gamma delta T cell lymphoma (PCGDTCL): a real world multi-institutional analysis of a rare malignancy. Blood [Internet]. 2019 [cited 2022 May 7];134:4028. Available from:https://doi.org/10.1182/blood-2019-130223

  41. Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2016 [cited 2022 May 10];51:205–11. Available from: https://www.nature.com/articles/bmt2015265

  42. Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas N, Jacob A, et al. Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. Blood Adv [Internet]. American Society of Hematology; 2021 [cited 2022 Apr 5];5:4198–210. Available from: http://ashpublications.org/bloodadvances/article/5/20/4198/476668/Next-generation-sequencing-based-monitoring-of

  43. Mehta-Shah N, Fehniger TA, Jacobsen ED, Peterson K, Kahl BS, Bartlett NL, et al. End of treatment peripheral blood T-cell receptor gene rearrangement evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas. Blood [Internet]. 2020 [cited 2022 Mar 22];136:30–1. Available from: https://www.sciencedirect.com/science/article/pii/S0006497118721174

  44. Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective. International T-Cell Project Haematologica. 2018;103:1191–7.

    CAS  PubMed  Google Scholar 

  45. Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry. Acta Haematol. 2020;143:40–50.

    Article  PubMed  Google Scholar 

  46. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.

    Article  CAS  PubMed  Google Scholar 

  47. O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.

    Article  CAS  PubMed  Google Scholar 

  50. Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. JCO [Internet]. Wolters Kluwer; 2012 [cited 2022 Apr 5];30:2190–6. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2011.38.0402

  52. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood [Internet]. 2014 [cited 2022 Apr 10];123:3095–100. Available from:https://doi.org/10.1182/blood-2013-12-542142

  53. Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Advances [Internet]. 2022 [cited 2022 Mar 30];6:920–30. Available from:https://doi.org/10.1182/bloodadvances.2021005899

  54. Castagna L, Pagliardini T, Bramanti S, Schiano de Colella JM, Montes de Oca C, Bouabdallah R, et al. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2021 [cited 2022 Feb 25];56:883–9. Available from: https://www.nature.com/articles/s41409-020-01133-5

  55. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741–7.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  PubMed  Google Scholar 

  57. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  CAS  PubMed  Google Scholar 

  58. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21:855–9.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Mehta-Shah N. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. ASH; 2020 [cited 2022 Feb 25]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper138542.html

  61. Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Network Open [Internet]. 2021 [cited 2022 Feb 25];4:e219807. Available from:https://doi.org/10.1001/jamanetworkopen.2021.9807

  62. Kim S-W, Yoon S-S, Suzuki R, Matsuno Y, Yi HG, Yoshida T, et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia. 2013;27:1394–7.

    Article  CAS  PubMed  Google Scholar 

  63. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med [Internet]. 2010 [cited 2022 Apr 6];363:2091–101. Available from: http://www.nejm.org/doi/abs/https://doi.org/10.1056/NEJMoa1004383

  64. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768–75.

    Article  PubMed  Google Scholar 

  65. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443–50.

    Article  CAS  PubMed  Google Scholar 

  66. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652–7.

    Article  PubMed  Google Scholar 

  67. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:218–24.

    CAS  PubMed  Google Scholar 

  68. Yang D-H, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biology of Blood and Marrow Transplantation [Internet]. 2009 [cited 2022 Apr 10];15:118–25. Available from: https://www.sciencedirect.com/science/article/pii/S1083879108005089

  69. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2010 [cited 2022 Apr 10];45:311–6. Available from: https://www.nature.com/articles/bmt2009165

  70. Han X, Zhang W, Zhou D, Ruan J, Duan M, Zhu T, et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res [Internet]. SAGE Publications Ltd; 2017 [cited 2022 Apr 10];45:290–302. Available from:https://doi.org/10.1177/0300060516676725

  71. Wu M, Wang X, Xie Y, Liu W, Zhang C, Ping L, et al. Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas. Int J Med Sci [Internet]. 2018 [cited 2022 Apr 10];15:867–74. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036090/

  72. Mamez A-C, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Journal of Hematology & Oncology [Internet]. 2020 [cited 2022 Feb 25];13:56. Available from:https://doi.org/10.1186/s13045-020-00892-4

  73. McIlroy G, Barmayehvar B, Kamarajah SK, George L, Gondal AZ, Malladi R, et al. Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma. Eur J Haematol. 2020;105:514–6.

    Article  PubMed  Google Scholar 

  74. Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54:877–84.

    Article  CAS  PubMed  Google Scholar 

  75. Zain J, Palmer JM, Delioukina M, Thomas S, Tsai N-C, Nademanee A, et al. Allogeneic hematopoietic cell transplantation for peripheral T-cell NHL results in long-term disease control. Leuk Lymphoma [Internet]. 2011 [cited 2022 Mar 26];52:1463–73. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441144/

  76. Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Oncology, 660 S. Euclid Ave., Box 8056-59, Saint Louis, MO, 63110, USA

    Nicole C. Foley & Neha Mehta-Shah

Authors
  1. Nicole C. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neha Mehta-Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neha Mehta-Shah.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Lymphomas

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foley, N.C., Mehta-Shah, N. Management of Peripheral T-cell Lymphomas and the Role of Transplant. Curr Oncol Rep 24, 1489–1499 (2022). https://doi.org/10.1007/s11912-022-01310-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01310-3

Keywords

Search

Navigation